International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 : 1-8 doi: 10.5281/zenodo.10068216
Original Article
Evaluation of Safety and efficacy of dietary fiber supplementary combinationin patients with chronic metabolic disorders (type-2 diabetes mellitus, dyslipidemia, overweight, obesity) and chronic GIT disorders (Constipation and Irritable bowel syndrome) with or without comorbidities for 4-12 weeks in outpatient department: an observational study
 ,
 ,
 ,
 ,
 ,
 ,
Published
Nov. 2, 2023
Abstract

Introduction: Intake of dietary fibre (DF) has beneficial effects on the risk factors responsible for development of several chronic diseases like IBS, obesity, colorectal cancer, type 2 diabetes and cardiovascular diseases. Hence this study was conducted with aim to evaluate the safety and efficacy of Fitofy, a soluble dietary supplement in various chronic metabolic disorders and chronic GIT disorders with or without other co-morbidities. Methodology: This prospective, observational, multicentric study was conducted for a period of one year from Jan 22 to Dec 22 including 120 patients. Results and discussion: Statistically significant improvement was seen in various efficacy parameters such asglycaemic control amongst diabetes mellitus patients and lipid profile in dyslipidaemia. Various efficacy parameters for obesity like weight, hunger level and waist circumference showed highly statistically significant fall from baseline. Significant reduction was observed in stool hardness and sensation of incomplete evacuation parameters in patients with constipation.  Spontaneous defecation and bowel frequency per week also showed good improvement.Good to excellent safety was observed in 97.19 % of the patient. No adverse event was reported by physician in any patients, A view of good to excellent tolerability was opined by 84.30 % patients. Conclusion: The dietary fiber supplement combination (DFSC) of inulin, partially hydrolysed guar gum, and resistant maltodextrin with proper diet therapy/modifications is found to be safe and effective in causing significant improvements in efficacy parameters of various chronic metabolic disorders like type 2 DM, dyslipidaemia, overweight/obesity, and chronic GI disorders.

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
267 Views
45 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved